Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 17/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL321350 | 1.00 | ROCK2 (0.41) | ROCK2KDM4ENPC1CYP1A2CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL321349 | 0.81 | ROCK2 (0.60) | ROCK2KDM4ENPC1CYP1A2CYP2D6 | |
| SCHEMBL13387316 | 0.80 | HDAC1 (0.41) | ROCK2KDM4E | |
| SCHEMBL10070344 | 0.79 | ROCK2 (0.65) | ROCK2KDM4ENPC1CYP1A2CYP2D6 | |
| SCHEMBL10070349 | 0.79 | ROCK2 (0.65) | ROCK2KDM4ENPC1CYP1A2CYP2D6 | |
| SCHEMBL2728807 | 0.73 | KDM4E (0.40) | ROCK2KDM4E | |
| SCHEMBL10277738 | 0.69 | ROCK2 (0.66) | ROCK2 | |
| SCHEMBL320957 | 0.68 | ROCK2 (0.45) | ROCK2 | |
| SCHEMBL320972 | 0.68 | ROCK2 (0.54) | ROCK2ROCK1 | |
| SCHEMBL320971 | 0.68 | ROCK2 (0.54) | ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590942-B1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-05-04 | — | — | EP | disclosed |
| US-9079880-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-14 | — | — | US | disclosed |
| US-20120178752-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178752-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, RHOA | ROCK2 2/4885KDM4E 1831/4885NPC1 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.